Correction: Genetic and clinical characteristics in Japanese hereditary breast and ovarian cancer: first report after establishment of HBOC registration system in Japan

[1]  C. Evers,et al.  Familial breast cancer: Genetic counseling over time, including patients´ expectations and initiators considering the Angelina Jolie effect , 2017, PloS one.

[2]  B. Karlan,et al.  Occult and subsequent cancer incidence following risk-reducing surgery in BRCA mutation carriers. , 2016, Gynecologic oncology.

[3]  Raymond Dalgleish,et al.  HGVS Recommendations for the Description of Sequence Variants: 2016 Update , 2016, Human mutation.

[4]  Tanja Fehm,et al.  Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancer , 2016, Journal of Medical Genetics.

[5]  N. Taira,et al.  The Japanese Breast Cancer Society clinical practice guidelines for epidemiology and prevention of breast cancer, 2015 edition , 2016, Breast Cancer.

[6]  R. Sarin,et al.  Current Status of the Management of Hereditary Breast and Ovarian Cancer in Asia: First Report by the Asian BRCA Consortium , 2015, Public Health Genomics.

[7]  Y. Miki,et al.  Prevalence and differentiation of hereditary breast and ovarian cancers in Japan , 2015, Breast Cancer.

[8]  K. Katanoda,et al.  Cancer incidence and incidence rates in Japan in 2009: a study of 32 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project. , 2015, Japanese journal of clinical oncology.

[9]  M. Pollán,et al.  Cumulative risk of second primary contralateral breast cancer in BRCA1/BRCA2 mutation carriers with a first breast cancer: A systematic review and meta-analysis. , 2014, Breast.

[10]  Jinbo Chen,et al.  Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers , 2014, Breast Cancer Research and Treatment.

[11]  Kathleen A Cronin,et al.  US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. , 2014, Journal of the National Cancer Institute.

[12]  D. Noh,et al.  The Korean Hereditary Breast Cancer (KOHBRA) study: protocols and interim report. , 2011, Clinical oncology (Royal College of Radiologists (Great Britain)).

[13]  A. Howell,et al.  Risk reducing mastectomy: outcomes in 10 European centres , 2008, Journal of Medical Genetics.

[14]  Y. Miki,et al.  Cross‐sectional analysis of germline BRCA1 and BRCA2 mutations in Japanese patients suspected to have hereditary breast/ovarian cancer , 2008, Cancer science.

[15]  Georgia Chenevix-Trench,et al.  An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA) , 2007, Breast Cancer Research.

[16]  J. Klijn,et al.  Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases. , 2007, European journal of cancer.

[17]  Sean V Tavtigian,et al.  Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  S. Tsuji,et al.  Mutational analysis of BRCA1 and BRCA2 and clinicopathologic analysis of ovarian cancer in 82 ovarian cancer families: two common founder mutations of BRCA1 in Japanese population. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  E. Lee,et al.  Uptake of risk-reducing salpingo-oophorectomy among female BRCA mutation carriers: experience at the National Cancer Center of Korea , 2015, Journal of Cancer Research and Clinical Oncology.

[20]  N. Taira,et al.  The Japanese Breast Cancer Society clinical practice guideline for epidemiology and prevention of breast cancer , 2014, Breast Cancer.

[21]  B. Carter.  Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) , 2013 .

[22]  C. Isaacs,et al.  BRCA1/2 mutations and triple negative breast cancers. , 2010, Breast disease.

[23]  永田 寛.  Haplotypes of BRCA1 mutation alleles in Japanese ovarian and breast-ovarian cancer families : A novel method for detecting BRCA1 associated ovarian cancer , 2002 .